Design, Conduct and Use of Patient Preference Studies in the Medical Product Life Cycle: a Multi-method Study -Supplementary Material
o Participants that were already interviewed in semi-structured interviews o Multiple patients from one family (but if in the end not enough patients are included, siblings can still be welcomed) • Book a venue/ meeting room that is neutral (hotel, patient organization, or university, not company or government), easily accessible to patients and that allows for a circle seating around a table • If possible, provide the information sheet to all participants in advance via email a week in advance (otherwise only before focus group on paper) • Provide the participants with instructions to get to the venue and room • Provide your/assistants' phone number (s) 
II. Focus group agenda
Everything below in Italic is to be said to the participants, everything in black is guidance and if applicable can be told to the participants in your own words. In bold the timing of actions is given; however, this is an indication of time, it is more important to finish the two first topics than to rush through the focus group and complete all three topics. In bold also, the slides to display is given. 4. 00:00 Slide 1. Welcome the participants while they arrive
• Create warm and friendly environment o Provide coffee and tea o Interact with participants, and stimulate interaction between participants • Make seating arrangements for participants according to their needs • Provide the information sheet and let them fill in the consent form and survey 5. 00:06 Slide 2. When all participants arrived and completed the forms, start the focus group with a general introduction:
• Welcome, my name is (your first name) and I will be your moderator today. In addition, I brought (first name of assistants) to help me with the focus group • My role as moderator will be to guide the discussion • The discussion that we will have today is on your involvement, or actually your preferences and how these preferences can be used in making drugs or medical devices, and in making them available to you • Today's discussion is part of a large European project with similar objectives • We want to have this discussion with you as patients (and caregivers), since we think it is important to know how you feel about using your preferences • The opinions collected today will be used to write reports and publications to inform companies, health authorities, researchers and other parties on how to use patient preferences • The focus group will take 1 hour to 1.5 hours • There will be a break in the middle of the discussion of 5-10 minutes 6. 00:08. Explain the rules:
• There are no right or wrong answers, only differing points of view • We are looking for your opinions and hope for a nice discussion • It is possible that you do not agree with all opinions, but it would be nice if you could listen respectfully to each other • We're audio recording, so it would be very helpful for the analysis if only one person is speaking at a time • Since this is an informal discussion, we will address each other only by their first name as indicated on the name cards • We ask you to turn off the sound of your phones • If there are any questions or terms that are used during the focus groups that are not clear to you, please let us know • So, we will now start the recording. Is that OK for everybody?
• First, to get to know each other, could everybody state their name and the city or village he/she is from? 
Everything below in Italic is to be said to the participants, everything in black is guidance and if applicable can be told to the participants in your own words. In bold the timing of actions is given; however, this is an indication of time, it is more important to finish the two first topics than to rush through the focus group and complete all three topics. 4. 00:00 Welcome the participants while they call in on the teleconference • Try to get every participant's name directly and welcome them • If participants try to participate without having signed the consent form, ask them if they can sign the consent form on spot and send a scan per e-mail within a couple of minutes. If this is not possible, ask them to leave the teleconference • Wait until all participants have joined for 5 minutes from start of teleconference 5. 00:06 When all participants arrived and completed the forms, start the focus group with a general introduction:
• Welcome, my name is (your first name), working as PhD researcher at (institute) and I will be your moderator today. In addition, also (first name of assistants) called in to help me with the focus group • My role as moderator will be to guide the discussion • The discussion that we will have today is on the assessment and use of information on patient preference studies when making decisions during the development of drugs or medical devices, and when making them available to patients • Today's discussion is part of a study within a large European project called IMI PREFER.
PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle. The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies. • We want to have this discussion with you as (name stakeholder), since we think it is important to know how you feel about using these preferences in the decision making at your institution(s) • The opinions collected today will be used to write reports and publications to inform companies, health authorities, researchers and other parties on how to use patient preferences • The focus group will take about 1.5 hours 6. 00:08 Explain the rules:
• There are no right or wrong answers, only differing points of view • We are looking for your opinions and hope for a good discussion • It is possible that you do not agree with all opinions, listen to each others points of view; each view is important and counts. Afterwards you are welcome to provide your view. • We're audio recording, so it would be very helpful for the analysis if only one person is speaking at a time • Since this is an informal discussion, we will address each other only by their first name • If there are any questions or terms that are used during the focus groups that are not clear to you, please let us know • So, we will now start the recording. Is that OK for everybody?
• First, to get to know each other, could everybody state their name and job title? 7. 00:10 Introduce the topic of patient preferences:
• Definition of the FDA: "The relative desirability or acceptability to patients of specified alternatives or choices among outcomes or other attributes that differ among alternative health interventions" • In other words, patient preferences are the basis of how patients choose a particular treatment over others. To make a choice, patients make trade-offs between a treatment's characteristics, weighing its advantages and disadvantages collectively. The importance of patient preferences in decision making seems to be increasing. However, actual application and integration of patient preferences in regulatory decision making is limited and not systematic. In addition, the possibilities and processes to incorporate patient preferences in regulatory decision making remain unclear. Therefore, I would like to ask you:
• • Thank and move on to next topic 3. 01:30 The following topic deals with stakeholder roles in patient preference studies.
• Who do you think should conduct a patient preference study aiming to inform regulatory decision making?
o What do you think should be the role of the sponsor of the patient preference study in the design of the study? o What do you think should be the role of the sponsor of the patient preference study in the conduct of the study? o What do you think should be the role of the sponsor of the patient preference study in the analysis of the study results? • In what manner do you think that conducting parties can influence patient preference studies? • If the interviewees express this is a concern: How do you think those influences can be reduced? • Summarize (very briefly) with confirmation • Review purpose and ask if anything has been missed • Thank participants for input III.III HTA 1. 00:15 Representativeness of the patient sample is an important quality indicator of patient preference studies. We would like to explore your understanding on this topic of representativeness. Therefore, I would like to ask you:
• What does a representative patient sample mean to you?
• How can representativeness of the patient sample be ensured? Besides representativeness of the patient sample we would like to know what characteristics, according to you, the patients should have to be able to participate in a patient preference study
• According to you, what would an ideal patient sample look like? o How does it depend on the research question being asked? • Summarize (very briefly) with confirmation • Review purpose and ask if anything has been missed • Thank and move on to next topic 2. 00:45 The importance of patient preferences in decision making seems to be increasing. However, actual application and integration of patient preferences in HTA and payer decision making is limited and not systematic. In addition, the possibilities and processes to incorporate patient preferences in HTA and payer decision making remain unclear. Therefore, I would like to ask you:
• 
SUPPLEMENTARY MATERIAL II -FOCUS GROUP ANALYSIS PLAN

II.I Steps and rationale behind the choice of the analysis method
The steps we undertook to select our analysis method included the following: , 1994) à This approach focusses on performing within and across case analyses to reveal similarities and differences among the different FGDs, which why we thought it was appealing to our study. However, we rejected this approach as it is also a very time consuming one; o Thematic analysis (Howitt, 2016) à Selected as our method.
Rationale behind the selection of thematic analysis:
1. Thematic analysis focusses on what has been said rather than how it was said; 2. Thematic analysis is accessible to novice researchers, as it is less demanding than other methods (e.g. thematic analysis does not involve the same level of sophistication in data collection and theory building as grounded theory); 3. Useful technique when: a. Data collection has finished; thematic analysis, as opposed to grounded theory, does not have the requirement that the data being collected are reviewed part-way through the analysis and new approaches to data collection are initiated; b. Data consists of detailed textual material (e.g. focus group transcripts); c. A broad-brush approach to analysis is desired (as opposed to some fine-grained approaches which characterize some qualitative methods);
II.II Protocol
Chosen method: Thematic analysis based upon "Qualitative Research Methods in Psychology" -Dennis Howitt
Core analyzing team ("CAT"): Eline van Overbeeke (EvO) and Rosanne Janssens (RJ)
Major steps in thematic analysis: 1. Data familiarization 2. Initial coding generation 3. Search of themes 4. Review of themes 5. Theme identification and labelling
Step-wise explanation:
Data familiarization
a. Howitt states that: i. Data familiarization can take place via several methods and will differ according to the details of the study. Ways of familiarizing with the data are: (i) being involved in the data collection stage, (ii) doing the transcription, (iii) playing the recordings repeatedly or (iv) re-reading the transcripts; ii.
Start think about what is happening in the data during this stage. These early thoughts may suggest ways in which the data might be coded; iii.
Use literal transcription (since thematic analysis is about what was said rather than how it was said); iv.
Novice researchers to do all the data collection and transcription themselves; b. Therefore, we will:
i. Become familiar with the data by: 1. Being present during the FGD as moderator or assistant to the moderator. Because of practical limitations, 2 FGDs were moderated by an external partner, which make the steps below critical to become familiar with those FGDs. These external partners were actively involved during the set-up the research (e.g. during the set-up of the protocol and FGD questions) as we had several discussions with them to inform them and ask about their feedback about our focus group questions and protocol. Next, because of the amount of the focus groups (n=8) and the different languages used, we chose to outsource the transcription and translation of the focus groups to a professional transcription company (TodayTranslations). 2. Thoroughly reading the transcript several times; ii.
Have the transcription done literally (at verbatim) by the transcription company; iii.
Have the transcripts checked for completeness and accuracy by moderator and/or assistants present during FGD; iv.
Convene and discuss in order to agree together about what was said in that particular part of the FGD, should there be difficulties in understanding the transcript. Should there be any remaining difficulties in understanding a certain part of the FGDs where neither one of EvO or RJ was present, we will contact the moderator and/or assistant present during that FGD to discuss and agree upon what was said.
Initial coding generation
c. Howitt states that: i. This stage does not aim at identifying the themes that the research will generate; initial codes are nothing more than labels that will describe the content of 1 or 2 lines, they are not sophisticated analyses of the data. However, ideas as to what the themes might be can already occur (as during any stage of thematic analysis); ii.
There are no "rules" describing that initial coding has to be done line-byline. Coding frequency depends on circumstances, if every line is not possible then every 2/3 lines is "all right"; iii.
Best if these codes are based on an abstraction rather than something concrete, the more conceptual (i.e. the less concrete, the more abstract) the codes, the better the final themes; iv.
Researchers can choose: 1. To work through the entirety of data or a subset of the data selected because it deals with a topic/matter of interest to the researcher; 2. Between a theory-led or data-led approach; v.
During this stage, it may be appropriate to re-name codes that are covering the same meaning so they have the same wording; vi.
After the initial coding has been done, researchers should put together all of the transcript which has received a certain code. Reviewing all coded text of a certain code can reveal that: 1. A coding label is not accurate/precise enough and needs to be renamed; 2. New codes need to be formed as some of the data in a certain code "does not match"; 3. Certain codes need to be combined to one code as the coded text below two codes is too similar. d. Therefore, we will:
i. Aim for 1 initial code every 2/3 lines; ii.
Use a data-led approach as described by Howitt, in which codes are primarily guided by careful analysis of what is in the data; iii.
Independently code the entirety of the data (n=8 FGDs), since there are two core analyzers; iv.
Convene after the independent coding of the data and perform steps vi.1, 2 and 3 together in order to agree upon the final list of initial codes
Search for themes based on initial codes
e. Howitt states that: i. This stage involves turning the initial codes into themes, which requires a lot of analytic work on the part of the researchers; ii.
Searching for themes involves searching for patterns among the initial codes; as they will probably notice that some codes are more related than others; iii.
Themes are the result of grouping and categorizing codes, which does not preclude that some codes might turn out to be very important and result in this code being an actual theme; iv.
Some themes may be very obvious from the initial codes, whereas sometimes methods of sorting might help, e.g. by writing down all the initial codes on separate slips of paper and creating piles of related codes. NVivo or Word might be used in this stage. f. Therefore, we will:
i. Each independently search for themes based upon the initial codes; ii.
Convene, discuss and agree upon the themes that we independently found.
Review of themes
g. Howitt states that: i. At this stage, there is a set of tentative themes which help to understand the data; ii.
In the case that these themes are not fully defined or refined at this stage, it is essential to examine these themes against the original data; iii.
Reviewing of themes involves organizing the data around the set of themes just as previously the data was organized around the codes; iv.
The possible scenarios of this stage are: 1. Modifying or abandoning the theme if there is very little in the data supporting the theme; 2. Dividing or subdividing the theme if the data in one theme actually imply two different themes or sub-themes; 3. Find a new theme if some of the data you initially believed were part of the theme does not fit. If this is the case, a check for applicability of these themes to this data as well as the entire data set is advised. h. Therefore, we will:
i. Divide the total number of transcripts among EvO and RJ; ii.
Separately go back to each of the assigned transcript and organize the text that was captured by the initial codes around our identified themes; iii.
Separately critically revise whether the theme should be abandoned, modified, (sub)divided or whether a new theme should be found; iv.
Any modification to our initial found themes will trigger a discussion between EvO and RJ and should this discussion lead to a modification of the initial list of themes, a check of the applicability of this modified list of themes to the entire data set will be done.
Theme definition and labelling
i. Howitt states that: i.
Although it might be easy to give a label to a theme, it might be more difficult to define exactly what a theme is; ii.
It is important to be able to conceptually distinguish one theme from another; iii.
It is likely to continue developing sub-themes at this stage; iv.
It is important to talk with other people about your analysis at this stage and allow them to question you and throw in ideas of their own. j. Therefore, we will:
i. Discuss and agree upon the final list of themes and sub-themes and our explanation to it. This will form the basis of the report (see 6.); ii.
Discuss within our CAT as well as with other persons how our themes differ from each other.
6. Report writing k. Howitt states that: i. The explanation and description of the themes in the final report of thematic analysis involve the selection of appropriate illustrations taken from the material which is associated with the theme; ii.
Criteria that may be applied for this selection are: 1. How 'typical' the material is of the data which belong to a particular theme; 2. How 'fit' the material is in relation to the theme; some excerpts might illustrate particular features of the theme better than others; 3. How 'eye-catching' the excerpt is; some data might be preferred to other excerpts as it is more vivid; 4. Some might prefer using excerpts from just one of the participants to get into more detail about that particular case iii.
It is helpful to indicate in the report the basis for your excerpt selection l. Therefore, we will:
i. Explain and describe in the final report the themes we identified; ii.
Use appropriate excerpts to illustrate these themes; iii.
Apply criteria ii.1, 2, 3 to select the excerpts we will use to describe the themes.
SUPPLEMENTARY MATERIAL III -LIST OF FINAL THEMES AND DEFINITIONS
III.I Patient focus group themes
Themes Definition 1. Healthcare issues that matter to patients All topics, issues, concerns, desires, needs, preferences important to patients in relation to their or others' healthcare 1.1 Medical product related issues All topics, issues, concerns, desires, needs, preferences important to patients in relation to medical products and their characteristics 1.2 Non-medical product related issues All topics, issues, concerns, desires, needs, preferences important to patients not directly in relation to medical products and their characteristics, but still relating to healthcare 1.2.1 Patient journey related issues All topics, issues, concerns, desires, needs, preferences important to patients relating to all the sequential steps in receiving healthcare Topics highlighted by patients and caregivers to consider in designing and conducting patient preference studies
Participant characteristics
The type of participants that should be included in patient preference studies according to patients and caregivers
Methodology
Considerations for the methods and instruments in patient preference studies according to patients and caregivers
Participants' information needs
The type of information patients and caregivers would like to receive before or when participating in a patient preference study
Factors influencing participation
Incentives, barriers, facilitators, hurdles that influence whether or not patients would like to participate in patient preference studies 3.5 Handling patient preference study data
The manner by which patient preference study data should be managed according to patients and caregivers taking into account privacy, confidentiality, data sharing and access
III.II Industry focus group themes
Themes Definition 1. Designing, conducting and reporting patient preference studies
Topics highlighted by industry representatives to consider in designing, conducting and reporting on patient preference studies
Research questions
The questions and topics that industry representatives hope patient preference studies will answer and the patient preference information they would find valuable to know 1.2 Sample considerations Factors to take into account when determining whose preferences should be measured 1.3 Methodology Considerations for the methods and instruments in patient preference studies according to industry representatives
Organizational considerations
Considerations for the methods and instruments in patient preference studies relating to budget, duration and timing along the medical product life cycle 1.5 Stakeholder roles in patient preference studies Stakeholder responsibilities and collaborations in patient preference studies according to industry representatives 1.6 Rigour, validity and robustness of patient preference studies How rigourous, valid and robust patient preference studies should be, aiming to inform decision-making of evaluators
Use of patient preferences in industry decisionmaking
What do industry representatives think about using patient preferences in industry, including their value, the methods to measure them and the potential application of patient preferences in industry 2.1 Value of patient preferences in industry The (added) value of patient preferences in industry processes and factors or situations influencing this value 2.2 Current conceptualization of patient preferences in industry How are patient preferences currently captured in industry processes
Position of patient preferences in industry
How do industry representatives see the use of patient preferences from (conducted) patient preference studies 2.4 Remaining questions Questions industry representatives raised but could not answer related to the use of patient preferences in their processes 3. Applications of patient preferences outside industry What do industry representatives say about using patient preferences by regulators and HTA
III.III Regulatory focus group themes
Topics highlighted by regulatory representatives to consider in designing, conducting and reporting on patient preference studies
Research questions
The questions and topics that regulatory representatives hope patient preference studies will answer and the patient preference information they would find valuable to know 1.2 Sample considerations Factors to take into account when determining whose preferences should be measured 1.3 Methodology Considerations for the methods and instruments in patient preference studies according to regulatory representatives
Organizational considerations
Considerations for the methods and instruments in patient preference studies relating to budget, duration and timing along the medical product life cycle 1.5 Stakeholder roles in patient preference studies Stakeholder responsibilities and collaborations in patient preference studies according to regulatory representatives 1.6 Reporting patient preference studies to evaluators How should patient preference studies aiming to inform decisionmaking be described and reported to evaluators?
Use of patient preferences in regulatory decisionmaking
What do regulatory representatives think about using patient preferences in regulatory, including their value, the methods to measure them and the potential application of patient preferences in regulatory 2.1 Value of patient preferences in regulatory processes The (added) value of patient preferences in regulatory processes and factors or situations influencing this value 2.2 Current conceptualization of patient preferences in regulatory processes How are patient preferences currently captured in regulatory processes
Position of patient preferences in regulatory processes
How do regulatory representatives see the use of patient preferences from (conducted) patient preference studies
Remaining questions
Questions regulatory representatives raised but could not answer related to the use of patient preferences in their processes
Applications of patient preferences outside regulatory processes
What do regulatory representatives say about using patient preferences outside their own processes • Encouragement of caregivers: LC and DM participants underlined how important the support and encouragement of family is to stimulate patients to participate in studies. DM participants in particular, stressed that often patients need to be motivated or even pushed by a family members to attend meetings and studies of any kind: "I am only here because of my carer and wife, [name of wife], who hasn't got DM1 [Myotonic dystrophy type 1] and she said, 'You are going to this thing' " (PA1_DM_UK).
III.IV HTA focus group themes
• Relationship with recruiting person: LC and RA patients explained that the level of trust and relation they have with the person that asks them to participate influences their willingness to participate. More specifically, receiving this question from their treating physician, whom they trust, motivates them to participate: "To encourage participation I believe also patients' trust in their oncologist is important, because when they phoned me I trusted them so I was willing to participate." (PA5_LC_IT). • Self-perception and disease acceptance: According to DM participants however, young DM patients are often self-conscious about their illness and do not want to attend big meetings where severely affected DM patients are present, as it confronts them with their disease: "Young people, sort of teen onwards, they are very self-conscious. They are very aware that they have got an issue and with my two, they don't like discussing it and don't want to be in an environment with other people, particularly wheelchairs and things, it is just a turn off for them" (CA1_UK_DM). Similarly, some LC participants mentioned that a lack of disease acceptance might hinder participation: "There are people who hide their disease, they receive the treatment but don't say it" (PA7_IT_LC).
• Interaction with patients: LC and DM participants mentioned that they are motivated to participate because of the possibility of sharing information, comparing experiences and just to go out and meet people: "So if I have to say why I would encourage someone else to attend, it is because you meet other patients and you realize you are not alone" (PA3_IT_LC). However, this view was not supported by some DM participants, who argued that DM patients often do not want to attend big meetings (see below: self-perception and disease acceptance).
• Financial compensation: Diverging views were expressed about whether or not financial compensations would incentivize patients to participate in preference studies; while some CVD participants argued that financial compensations are not needed, because they have a personal interest and "gain" from participating in preference studies, and because of the convenience of participating in preference studies situated in hospitals: "But this is not something you should get paid for, because you don't make any effort" (PA2_RO_CVD), one RA participant argued that financial compensations should be provided if the preference study interferes with work and daily activities: "I think that if people are paid, because everyone is working and is busy and... I think that it is something like this, that is, that one gets a benefit from it personally" (PA1_SE_RA).
• Convenience: Participants from all disease areas mentioned different aspects impacting their participation in preference studies related to the convenience of the study. According to RA and DM patients, the time investment of participation should be kept at a minimal level and hence, questionnaires should be as short as possible. One RA patient added that longer questionnaires, interfering with work life, should be financially compensated. Physical constraints (such as sleepiness and digestive problems), a long travel distance and an inconvenient time during the day were barriers to participating mentioned by DM patients: "It is a physical constraint and that is not got to do with her willingness or not to participate, it is just the physical side, this continuing fatigue" (PA1_UK_DM). Some DM, CVD and LC patients suggested organizing preference studies in a hospital setting, as this would allow them to combine their participation with hospital stays or visits: "We did not give up a profession, a meal, a study, an activity of sorts to come here, we stay with you for 7 days or 10 days, for as long as we are hospitalised" (PA2_RO_CVD). Some DM participants added that besides hospitals being "the easiest place for them to go to" (CA1_UK_DM), they are also familiar to DM patients.
• Attractiveness: DM participants spoke about how some young DM patients dislike big events where they are confronted with their illness. In order to increase the attractiveness and hence, the participation of young DM patients into the preference study, some DM participants suggested de-formalizing the preference study: "If you could de-formalise it (…) something like a barbeque or a party (…) music, they all love music" (CA2_UK_DM). • Feedback on results: DM participants argued that receiving information on the study results would make it worthwhile for them to participate: "It would be nice to know, get some global feedback and individual feedback because it comes back to this apathy that for me, you start to think, 'Oh, it is not worth it'" (PA1_UK_DM). Further, this information ideally comes in the form of a short summary: "I don't want a massive amount. A few short summaries is what I would be looking for rather than the detail" (CA2_DM_UK).
